Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
Market Access as a Driver of Biotech Value in 2026
Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
-
Barriers to CAR-T Access in Medicare
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
-
PBM Reform in the Commercial Insurance Market: Understanding the Federal Budgetary Impact
Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
-
Case Study: Educating on Combination Product Access
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.
-
Case Study: Launch Planning and Readiness
How program management and strategic alignment prepared a biopharma company for NDA submission and launch.
-
Case Study: Reimbursement & Market Access — Supporting Products with Required Imaging
How a manufacturer integrated imaging requirements into its access and patient support strategy.
-
Case Study: Leveraging Payer Insights to Shape Market Access Strategies and Tactics
How payer research helped refine value messaging, pricing strategy, and evidence plans.
-
Case Study: Preparing and Executing a Comprehensive 340B Contract Pharmacy Strategy
How a pharmaceutical company built a compliant, scalable 340B contract pharmacy program.
-
Case Study: Digital Phenotyping — Harnessing AI & Unstructured Data to Revolutionize Life-Saving Diagnostics
How AI-driven EMR analysis helped identify high-risk cardiovascular patients and support earlier intervention.
-
Case Study: Linking Real-World Datasets to Identify Cost Drivers in Lung Transplantation
How a biotechnology company used real-world data analysis to uncover cost drivers and validate the economic impact of EVLP.
-
Why Real-World Evidence Is Reshaping the Economics of Drug Pricing
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.
-
Deal-Driven Policy, Direct-to-Patient Models, and State Momentum: Preparing for 2026
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.